| 產(chǎn)品編號(hào) | bsm-51578M |
| 英文名稱(chēng) | BCL10 Mouse mAb |
| 中文名稱(chēng) | BCL10單克隆抗體 |
| 別 名 | Bcl-10; B cell CLL/lymphoma 10; B cell lymphoma/leukemia10; B-cell leukemia/lymphoma 10; Bcl 10; c E10; c-E10; C81403; CARD containing apoptotic signaling protein; CARD containing molecule enhancing NF kappa B; CARD containing molecule enhancing NF kB; CARD containing molecule enhancing NFkB; CARD containing proapoptotic protein; CARD like apoptotic protein; CARMEN; Caspase recruiting domain containing protein; cCARMEN; cE 10; cE10; CED 3/ICH 1 prodomain homologous E10 like regulator; CED3/ICH1 prodomain homologous E10 like regulator; Cellular E10; Cellular homolog of vCARMEN; CIPER; CLAP; hCLAP; Mammalian CARD containing adapter molecule E10; mE 10; mE10; R-RCD1; BCL10_HUMAN. |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 信號(hào)轉(zhuǎn)導(dǎo) 細(xì)胞凋亡 細(xì)胞周期蛋白 轉(zhuǎn)錄調(diào)節(jié)因子 |
| 抗體來(lái)源 | Mouse |
| 克隆類(lèi)型 | Monoclonal |
| 克 隆 號(hào) | G56 |
| 交叉反應(yīng) | Human,Mouse |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,Flow-Cyt=1:50-100
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 26 kDa |
| 檢測(cè)分子量 | |
| 細(xì)胞定位 | 細(xì)胞漿 細(xì)胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human BCL10: 1-130/233 |
| 亞 型 | IgG1,Κ |
| 純化方法 | affinity purified by Protein G |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
This gene was identified by its translocation in a case of mucosa-associated lymphoid tissue (MALT) lymphoma. The protein encoded by this gene contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB. This protein is reported to interact with other CARD domain containing proteins including CARD9, 10, 11 and 14, which are thought to function as upstream regulators in NF-kappaB signaling. This protein is found to form a complex with MALT1, a protein encoded by another gene known to be translocated in MALT lymphoma. MALT1 and this protein are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy. [provided by RefSeq, Jul 2008] Function: Promotes apoptosis, pro-caspase-9 maturation and activation of NF-kappa-B via NIK and IKK. May be an adapter protein between upstream TNFR1-TRADD-RIP complex and the downstream NIK-IKK-IKAP complex. Is a substrate for MALT1. Subunit: Contains 1 CARD domain. Subcellular Location: Cytoplasm > perinuclear region. Membrane raft. Appears to have a perinuclear, compact and filamentous pattern of expression. Also found in the nucleus of several types of tumor cells. Colocalized with DPP4 in membrane rafts. Tissue Specificity: Ubiquitous. Post-translational modifications: Phosphorylated. Phosphorylation results in dissociation from TRAF2 and binding to BIRC2/c-IAP2. Phosphorylated by IKBKB/IKKB. DISEASE: Note=A chromosomal aberration involving BCL10 is recurrent in low-grade mucosa-associated lymphoid tissue (MALT lymphoma). Translocation t(1;14)(p22;q32). Although the BCL10/IgH translocation leaves the coding region of BCL10 intact, frequent BCL10 mutations could be attributed to the Ig somatic hypermutation mechanism resulting in nucleotide transitions. <>brNote=Defects in BCL10 are involved in various types of cancer. Mesothelioma, malignant (MESOM) [MIM:156240]: An aggressive neoplasm of the serosal lining of the chest. It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. Note=The gene represented in this entry may be involved in disease pathogenesis. Similarity: Contains 1 CARD domain. SWISS: O95999 Gene ID: 8915 Database links: Entrez Gene: 8915 Human SwissProt: O95999 Human |
| 產(chǎn)品圖片 |
25 ug total protein per lane of various lysates (see on figure) probed with Bcl10 monoclonal antibody, unconjugated (bsm-51578M) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.
Paraformaldehyde-fixed, paraffin embedded Human Tonsil; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with BCL10 Monoclonal Antibody, Unconjugated(bsm-51578M) at 1:200 overnight at 4°C, followed by conjugation to the bs-40296G-HRP and DAB (C-0010) staining.
Paraformaldehyde-fixed, paraffin embedded Human Gastric Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with BCL10 Monoclonal Antibody, Unconjugated(bsm-51578M) at 1:200 overnight at 4°C, followed by conjugation to the bs-40296G-HRP and DAB (C-0010) staining.
Paraformaldehyde-fixed, paraffin embedded Human Colon Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with BCL10 Monoclonal Antibody, Unconjugated(bsm-51578M) at 1:200 overnight at 4°C, followed by conjugation to the bs-40296G-HRP and DAB (C-0010) staining.
Paraformaldehyde-fixed, paraffin embedded Human Liver Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with BCL10 Monoclonal Antibody, Unconjugated(bsm-51578M) at 1:200 overnight at 4°C, followed by conjugation to the bs-40296G-HRP and DAB (C-0010) staining.
Paraformaldehyde-fixed, paraffin embedded Human Lung Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with BCL10 Monoclonal Antibody, Unconjugated(bsm-51578M) at 1:200 overnight at 4°C, followed by conjugation to the bs-40296G-HRP and DAB (C-0010) staining.
Blank control:Hela.
Primary Antibody (green line): Mouse Anti-BCL10 antibody (bsm-51578M)
Dilution: 1:100;
Secondary Antibody : Goat anti-mouse IgG-FITC
Dilution: 0.5ug/Test.
Protocol
The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 90% ice-cold methanol for 20 min at -20℃.The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
|
